Derma Sciences (DSCI) Tops Q2 EPS by 6c

Derma Sciences (NASDAQ: DSCI) reported Q2 EPS of ($0.36), $0.06 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $22.6 million versus the consensus estimate of $21.66 million.

For earnings history and earnings-related data on Derma Sciences (DSCI) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• BWS Financial Starts Capstone Energy Plus (CEPL) at Buy
• Sanuwave Q2 2026 revenue tops revised guidance range